Medtronic plc (MDT) on Q1 2021 Results - Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. And welcome to the Medtronic First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to Ryan Weispfenning, Vice President, Head of Investor Relations. Please go ahead, sir. Ryan Weispfenning: Thank you. Good morning, and welcome to Medtronic's fiscal year 2021first quarter conference call and webcast. Geoff Martha's first quarter as Chief Executive Officer. Another first today is that we're presenting our prepared remarks by video. We hope that you'll appreciate this new format, and please let me know if you have any feedback. Today's earnings call should last about an hour. Geoff along with Karen Parkhill, Medtronic Chief Financial Officer, will provide comments on the results of our first quarter, which ended on July 31, 2020. After our prepared remarks, we'll take questions from the analysts. Before I turn it over to Geoff, here's a few things to keep in mind. Earlier this morning, we issued a press release containing our financial statements and a revenue by division summary. We also issued an earnings presentation that provides additional details on our performance. During today's prepared remarks and Q&A session, many of the statements we make may be considered forward-looking statements and actual results may differ materially from those projected in any forward-looking statement, given risks and uncertainties, including those related to the impact COVID-19 has had and is expected to continue to have on our business. Additional information concerning factors that could cause actual results to differ is contained in our periodic reports and other filings that we make with the SEC. And we do not undertake to update any forward-looking statement. Unless we say otherwise, all year-over-year revenue comparisons mentioned during this call are given on an organic basis which adjust for three things. First, the inorganic impact of our Titan Spine acquisition, second, foreign currency. And third the extra week that we had in the first fiscal month this quarter, compared to the first quarter of fiscal year 2020.The extra week is a result of our 52-53 week fiscal year calendar, which results in an extra week every five or six years. Finally, reconciliations of all non-GAAP financial measures can be found in the attachment to our earnings press release or on our website at investorrelations.medtronic.com. With that, I'll turn it over to Medtronic Chief Executive Officer, Geoff Martha. Geoff? Geoff Martha: Okay. Thanks, Ryan. And I appreciate everyone joining us today. But before we dive into our Q1 results, I want to once again thank the frontline healthcare workers who continue to fight COVID-19 every day. We are thankful beyond words for your sacrifice and tireless resolve. I also want to acknowledge all of the Medtronic employees, who have gone that extra mile to support our customers and patients during this difficult time. Thank you for showing that our mission written 60 years ago, still inspires us and really defines who we are as a company. I also want to acknowledge the wildfires burning in Northern California. Medtronic has been a long time member of the Santa Rosa Community, and while our operations aren't currently affected, our thoughts are with those heroes battling these terrible blazes and the people affected, including some of our employees. We hope for a quick containment, and we're standing by ready to assist. Okay, now let's switch gears to Q1. Our results reflect a very strong recovery from the depths of the pandemic that we saw back in April. Procedure volumes began to recover this quarter in multiple markets around the world. And we drove market share gains in a number of our large businesses. Our revenue declined 17% on an organic year-over-year basis. And our adjusted EPS of $0.62, while down 51% was well ahead of expectations. We've seen a faster than expected recovery. Our pipeline is kicking in and we're increasing our cadence of tuck-in M&A. But most importantly, we're finding a new gear at Medtronic, and we're becoming a more nimble and a more competitive organization. And in the coming weeks, you're going to hear more from me on this topic, as we begin to outline the new Medtronic. When the pandemic first hit, we had to postpone our biennial Investor Day, originally scheduled for June. Well, today, we're announcing that we've rescheduled the meeting, and we're now going to host a virtual meeting with you on Wednesday, October 14. We're going to use that opportunity to lay out where we're headed, including a deeper dive on our pipeline now that it's coming to fruition, as well as the actions we're taking to simplify the company. So we look forward to being with you virtually at least on October 14. Now, I'd like to do something a little different than our past earnings calls, and lead with the discussion of market share. Collectively, our results in the month of June were stronger than many of our competitors, and that strength continued into July and now into the first few weeks of August. In some businesses, we're benefiting from the actions we took at the start of the pandemic, to better partner with our customers. In other businesses, we're seeing the benefit of new product launches, as our pipeline kicks in across the company. In fact, we've already had over 130 regulatory approvals this calendar year in the U.S. and Europe, Japan and China. We've included a key approval slide in our earnings presentation that outlines all of this. We're gaining share in our largest businesses like Spine and CRHF, Pacing and High Power. For example, our U.S. Core Spine business declined in the high-single-digits, which was better than the market. We estimate that we gained over a half a point of share in the second calendar quarter. Our differentiated offerings of enabling technologies, which includes robotics, imaging and navigation, combined with our implants is reshaping the spine industry. In CRHF, we estimate that we gained significant implant share in both the High and Low Power markets in the second calendar quarter, with the greatest gains coming in the U.S. Micra, our leadless pacemaker grew in the low-40s globally, and approximately 60% in the U.S. While many have been focused on how Micra is expanding the market and taking share, our new Cobalt and Crome, ICD and CRT-D platforms are also beginning to drive meaningful implant share in High Power. We launched these devices mid-quarter in the U.S. and we're now working with a growing number of providers across the country, who have not implanted with Medtronic in years. Electrophysiologists are choosing Cobalt and Crome for their unique AF and heart failure therapeutic algorithms. The high-40 joule output, extended battery longevity, heart failure management capabilities, as well as their blue sync remote programming and remote device management. These features provide layers of competitive advantage for us. We saw a 35% sequential increase in smart sync accounts globally. And our proprietary remote control programming technology, which was launched in the previous quarter, saw a six fold increase in adoption sequentially. In addition, utilization of our TYRX absorbable antibacterial envelopes increased by 9 points sequentially, to 50% of our U.S. transcatheter pacing and ICD implants, as hospitals are focusing on minimizing patient rehospitalization rates during COVID. We've also begun to return to sequential implants share capture and TAVR, one of our largest growth drivers. In the second calendar quarter, we maintained our share and market leadership in Europe, and gained approximately 1 point of implant share sequentially in the U.S., as we opened new NCD accounts and saw great response from interventional cardiologists and cardiac surgeons to the bicuspid, leaflet immobility and hemodynamic clinical data that was shared at ACC in the spring. In fact, we've received approval from the FDA just last week to remove bicuspid labeling limitations for low risk TAVR on the strength of these data. This labeling change complements the approval we received earlier this summer, as the only CE Mark TAVR system, with a bicuspid indication for intermediate risk patients. These are important regulatory milestones given the large size of the bicuspid patient population, including 60% of the low risk population. I'll also point out the share gains that we're seeing in our Pain Stim business, within neuromodulation, where we've been rolling out our new DTM therapy. The superiority data that we have for DTM is resonating in the market. We're taking advantage of this by focusing on customers that either don't use Medtronic devices, or split their business across multiple companies. And we're having great success with this strategy. In fact, almost half of our DTM implants in the quarter occurred with these type of customers. And equally important, our SCS trials, which are a predictor of our future implants, were ahead of our expectations and even caught up to prior year levels in June. This bodes really well for our Pain Stim business going forward. So while we're driving share gains in many important businesses, there are also areas that we need to improve. In DBS and Pelvic Health, while we lost share in the quarter, we're very bullish on where we're headed. In DBS, we received FDA approval for our Percept PC deep brain stimulation system with brain sense technology, in late June. Percept is the first DBS to record brain signals while delivering therapy, and we expect this to drive share gains in this high growth market going forward. In fact, we believe this is the beginning of a multi-year run in DBS, with our directional lead launching next year, followed by a Closed-Loop DBS system. We're redefining the standard-of-care and creating a significant technology gap between us and our competitors. In Pelvic Health, we just received FDA approval for Interstim Micro device, which has important features over the competition. Our device is 50% smaller, it recharges far faster. And importantly, the recharger doesn't need to be perfectly aligned for a successful charge. Additionally, Medtronic is the only company to offer physician practices, the choice of recharge and recharge free. And this is very important in the neuromodulation space. The physicians' feedback on our InterStim Micro rechargeable product has been universally positive. And there are several early indications that our share in the U.S. is rebounding quickly, much like we saw in Europe following the Micro launch earlier this year. In just a few weeks, we're winning back accounts and we're seeing cases where our competitors device is being explanted and replaced by Micro. We've been waiting for this. Patients now have the ability to choose a smaller, better rechargeable product. Physician practices to prefer to deal with one company. And our team is enjoying taking back the share. Finally, in diabetes, look, we're missing out on the better growth of this market, and nobody at Medtronic is comfortable with this dynamic. And we're pushing on several fronts to advance our technology. We're actively increasing both our near and our long-term growth opportunities, through increased organic investment, innovative funding with our recently announced Blackstone partnership, and inorganic activity, highlighted by the announcement earlier this month of our pending acquisition of Companion Medical. Companion Smartpen technology expands our ecosystem to include the multi daily injection portion of the diabetes market, with a patient population that is nearly 12 times larger than that that use insulin pumps. But make no mistake, we are still very focused on regaining technology leadership in the pump and the sensor market. However, we're also going to meet patients where they are, and provide them with real time data guided support. We expect to build a system that combines in pen with our Smart CGM technology, including our neutrino and clue artificial intelligence algorithms. All of this designed to deliver better outcomes and reduce the burden of managing the disease for MDI patients. See, Companion is just one more example of how we're going on the offensive as a company through an increased cadence of tuck-in acquisitions. In fact, in addition to Companion, we've done two other major tuck-in acquisitions this calendar year, with Digital Surgery and Medicrea. Combined, these three deals totaled approximately $1 billion in total consideration. Data and analytics are the next big frontier in surgery. That's why we acquired the pioneering technology company, Digital surgery, the leader in surgical artificial intelligence. We're integrating their technology into our soft tissue robotic assisted surgery system, and also intending to use their surgical video management and clinician decision support solutions beyond robotics. In fact, we plan on a limited launch this fall for the Touch Surgery Enterprise, which is an extremely easy-to-use, surgical video capture solution, paired with a computer and connected to the cloud. Medicrea, a pending acquisition we announced last month has differentiated technology that incorporates artificial intelligence into surgical planning for spine cases, and then uses the plan to create personalized spinal implants. With Medicrea, Medtronic will be the first company to offer an integrated spine surgery solution that includes AI-driven surgical planning, personalized implants and robotic assisted surgical delivery. This further extends our competitive advantage in Spine. We will continue to use the strength of our balance sheet to supplement our organic growth, and help drive increased and sustained revenue growth into the future. Next, let's turn to our pipeline, which is not just a share taking pipeline, it expands the total addressable market for Medtronic, as we intend to bring innovative technology to large healthcare opportunities, such as hypertension and cancer screening. So starting with our cardiac and vascular group, I've already mentioned the impact that our recent launches of Micro AV and Cobalt and Chrome are having in our CRHF division. But in addition to that, our next generation cardiac diagnostic LINQ II, received FDA approval in the quarter. And we began the limited U.S. release and expect the full market launch by calendar yearend. In our cardiac ablation solutions business, we started the European limited release of our Diamond Temp Cardiac Ablation system, with its unique closed-loop temperature-controlled RF system. And in June, our Arctic Front Advance Cryo system, became the first ablation system to receive FDA approval to treat patients with persistent AF. And this Saturday, results from our stop AF first trial, which studied our Cryoballoon as a first line treatment for paroxysmal AF, will be presented virtually as a late breaking trial at ESC. And in our coronary business, our Resolute Onyx Drug Eluting Stent became the first and only stent to receive CE Mark for one month DAPT treatment, for high bleeding risk patients. And we expect FDA approval for this differentiated labeling later this calendar year. In CVG, we also resumed a number of important clinical trials that were on hold due to the pandemic, including our pivotal trials for our extra vascular ICD, our Intrepid Transcatheter Mitral Valve, our PulseSelect Pulsed Field Ablation system, and our Symplicity Spyral renal denervation system. In our ON MED renal denervation trial, half of the sites have resumed enrollment, and we're aiming to complete the trial and present the data next calendar year. We're in the lead with Ardian, and this represents a multibillion dollar opportunity to better treat the millions of patients around the world, who suffer from hypertension. As I've already mentioned, we're now launching a number of products across the restorative therapies group, like the DTM spinal cord stimulator, our InterStim Micro sacral nerve stimulator and our Percept PC deep brain stimulator. Look, RTG is on a roll. And we expect these products to drive growth and take share going forward. And we intend to keep the RTG momentum going well into the future. We're making large investments in new products for neurovascular, for ENT and for enhancements to our Mazor X spinal robotic system. In diabetes, we continue to execute on our near-term pipeline. We're on track for the Minimed 770G approval later this summer. We've received CE Mark approval for our Minimed 780G, advanced hybrid closed-loop system and we'll launch this fall. We also continue to make meaningful progress on our sensor pipeline. Our U.S. pivotal trial for synergy is now underway. Enrollment is going well, and we're getting great feedback on this disposable sensor that is 50% smaller than our current product. In our Minimally Invasive Therapies group, we continue to make progress on bringing our soft tissue robotic system to market. Our final validation and verification testing is going very well. And our surgeon feedback continues to be positive. On the last earnings call, we told you that our timeline had been disrupted by COVID-19, but we've been managing through this and mitigating the impact to our timelines. In fact, we expect to be in a position to file for CE Mark and U.S. IDE approval in the first calendar quarter of 2021. Now COVID could change that, but we thought it was important to update you as to where we are today, and let you know that we have a high level of confidence as we move towards commercialization. In MITG, we've also been rapidly developing new solutions to treat COVID-19, including adding remote management capability to our Puritan Bennett 980 ventilator, integrating nalcor pulse oximetry sensors with label therms, closed-loop high flow ventilation system, and enhancing our vital sync remote monitoring solution to allow caregivers to remotely monitor our pulse oximetry and our capnography devices through a mobile application. Many of these features, they were developed in days and weeks, which in the past might have taken us months and quarters. But because we found new ways, we're moving faster. We're partnering with others, whether that's on technology development or in supply chain relationships. We're working with our regulators to ensure they have everything they need to streamline their decision makers, and our own people are stepping up across the company. As one example, we increased our internal ventilator production fivefold in a matter of just a few months, from 200 a week to over 1,000 a week. This is what I mean, when I say Medtronic is finding a new gear. We've been operating with a high sense of urgency, and we're going to carry this forward. I've discussed in the past how our organization needs to simplify and become less bureaucratic. In the coming weeks, you're going to hear more about the actions we're taking to become a more nimble and a more competitive organization, empowering our business units, while also allowing them to take advantage of Medtronic's global scale. I'm really excited about this direction. And I'm convinced that by empowering our general managers, we can become more competitive, we can accelerate our innovation, we can serve our customers better, and we're going to unlock a lot of value for our shareholders. So, with that, let me now ask Karen to take you through a discussion of our first quarter financials and our outlook. Karen, over to you. Karen Parkhill: Thank you. As Geoff mentioned, our first quarter organic revenue decline of approximately 17% was better than initially expected, and an 8 point improvement over last quarter. CVG and RTG, in particular had double digit improvement from their fourth quarter decline. Within CVG, cardiac rhythm and heart failure improved the most declining in the mid-teens, thanks to both rebounding procedures, and share capture from new products. And within RTG, core spine and pain stim had strong sequential improvement, with the bounce back of these more deferrable procedures in the United States. I would note that our organic revenue decline excludes the benefit we received from an extra week of sales in the first fiscal month of the quarter, which we estimate added approximately $360 million to $390 million in revenue, less than our extra week would have been without a pandemic. But it's important to know this benefit was offset by our plan to reduce customer both purchases. Hopefully, you'll recall from prior earnings calls that we intended to use a good portion of the benefit from this extra week to reduce the practice of customers placing large bulk orders, as we're working to better balance these across the quarter. We began this process earlier than planned, due to depressed demand with COVID in the fourth quarter, and we still had some residual reduction in customer inventory levels this quarter. As we look ahead, the vast majority of the bulk reduction is behind us. There are only a small number of areas, such as our TAVR business, where we've been transitioning to a consignment model in select U.S. accounts, and where we should see another quarter or two of modest headwind. On the bottom line, our adjusted EPS was $0.62, a decline of 51% including an estimated benefit from the extra week of approximately $0.06 to $0.10. As our revenue improved throughout the quarter, we saw a strong flow through to our bottom line, resulting in EPS well ahead of expectations. That said, with a decline in revenue, we continue to see deleveraging down our P&L. Several of our plants ran at less than full capacity, resulting in a larger period expense of our fixed overhead costs, and a decline in our gross margin as we expected. We also had increased SG&A and R&D spend, as I signaled last quarter, given both the extra week and the increased investment we are making in our pipeline and product launches. As a result, our operating margin was 16.5%, down 12 points year-over-year, but an improvement of 40 basis points from last quarter. Turning to our balance sheet, our financial position is strong, with ample liquidity to act on opportunities. We remain focused on investing, both organically and in organically through tuck-in acquisitions and minority investments, to drive our long-term growth strategies. We've increased our cadence of M&A, and we're increasing our level of R&D investment, with partners like Blackstone Life Sciences, who will invest more than $300 million over the next several years, to help us accelerate specific pump and CGM programs and diabetes. These creative strategies will enable us to accelerate our planned investment and our growth. I view this as a key win for our company, the patients we serve and you, our shareholders. Turning more to the macro level, we expect both organic and inorganic investments to fuel a longer-term revenue growth acceleration, creating strong returns for our shareholders, supplemented by our growing dividend. As an S&P dividend aristocrat, we've increased our dividend for 43 years, and our current yield of 2.3% is in the upper quartile of S&P 500 healthcare companies. Looking ahead, the uncertainty of the COVID-19 pandemic continues to make it difficult to provide our traditional, annual and quarterly guidance. However, as we shared last quarter, we intend to be as transparent as possible, to help you understand how we're thinking about the trajectory of our business. We've experienced a faster than expected recovery. On the topline, May was better than April and June was better than May. And that improvement has continued into July and August. While there's still uncertainty regarding to recovery, if these trends hold, we would expect our second quarter organic growth rate to improve at a rate similar to what we saw between the fourth and the first quarters, where the fourth was down 25% and the first declined 17%. From there, we expect sequential improvement in the third and fourth quarters. And we still expect to be back to normal growth in the fourth quarter on a two-year stacked basis. When we look at our second quarter expectations by group, MITG should be better than the company average, given continued increased demand in our respiratory business and increased volumes in surgical innovation. CVG has the potential to be a little better than company average, given its new product introductions. Diabetes is expected to perform roughly in line. And RTG could be a little below the total company, given its high mix capital equipment sales, but we're still seeing some sequential improvement. Looking at the P&L, we're investing to support numerous product launches. And we're investing in R&D programs to ensure our pipeline remains full. Despite the pandemic, we're not pulling back. Instead, we're focused on making the necessary investments to accelerate our revenue growth and ensure the long-term health of our company. Having said that, we could see a couple of points of sequential improvement in both our gross and operating margins in the second quarter compared to the first. And we expect continued margin improvement through the second-half, until we return to more normal margins sometime toward the end of our fiscal year. Regarding currency, the picture has improved with a weakening dollar. On revenue, assuming recent rate hold constant, our second quarter impact flips to a slight tailwind, after two years of a headwind, and a full year benefit is now over $100 million. On the bottom line at recent rates, the second quarter headwind should be similar to the first, and the full year has improved by about a nickel from the $0.20 impact, I mentioned last quarter. 5As I wrap-up, I would want you to take away that whatever the recovery looks like, we intend to outpace our end market. We're focused on competing and winning, and we have the industry's best and broadest pipeline, the resources and the people to do it. The future is bright. And I'm proud to be part of this team driving our imperatives to fuel our growth and also fulfill our mission, ensuring that millions of people around the world can benefit from our products and services. Back to you, Geoff. Geoff Martha: Okay. Thanks, Karen. I hope you got a sense today for our recovery trajectory, as well as how we're changing at Medtronic. And we'll continue this conversation at our Investor Day on October 14. During the pandemic, our entire leadership team came together to determine how we could better serve our customers and evolve our culture. We worked together to find this new gear, and we're on our way to becoming a more nimble and competitive organization. We're playing offense, and we're energized to use this moment, when our pipeline is kicking-in, to expand our markets and take share. And importantly, we're driving towards faster and broader topline growth, not just as we emerge from the pandemic, but sustainable growth over the long-term. So, with that, let's now move to Q&A. In addition to Karen and me, we also have our four group presidents: Mike Coyle, Bob White, Brett Wall, and Sean Salmon, here to answer your questions. As usual, we want to get to as many questions as possible, so please help us by limiting yourself to one question, and if necessary, a related follow-up. If you have additional questions, please contact Ryan and our Investor Relations team after the call. Operator, first question please? Operator: Your first question comes from the line of Vijay Kumar with Evercore ISI. Vijay Kumar: Hey guys, thanks for taking my question. And Geoff, congrats on a solid earning per share. I had one question and a follow-up, I'll ask them and then the same question. I guess, it's interesting you started your comments with a focus on market share, Geoff. One, is the implication here that Medtronic -- Medtronic's focus on market share, the implication is that you guys need to be grown in line to above market in markets? Because I do feel like one of the better thesis is Medtronic is too big to grow. So, is that about to change with this focus on market share? And what is driving this right? Is this -- has something changed here internally to drive this focus on market share to see that, being reflected in numbers? And as a follow-up, I think of robotic timeline in a calendar first quarter '21. I think the original time line was mid of this year, this five to six months, I just want to make sure that there's just purely a function of COVID and software issues, et cetera, they've been resolved. And what does it mean for robotic market share, right? If you're focused on market share process segments, it doesn't mean that Medtronic should gain it's fair share, and perhaps more than fair share of robotic surgery? Thanks, and I'll stop there. Geoff Martha: Okay. Thanks, Vijay. I appreciate the questions. On the first one, regarding market share, you're asking why the focus, what's changed. We spent the last couple of years talking about our pipeline. And this has been a big focus on the company. And like we've talked about our pipeline is the best it's been in a long-time. And as we went through this CEO transition, we spent a lot of time with the team on Zoom calls all the time. And we're determined to make this pipeline count, not just for patients, our customers but for shareholders. And so we feel that sometimes our market share isn't commensurate with our technology, meaning our technology should yield more market share. And, and this is an organizational focus that we want to take on, in terms of -- is really focused on -- really a deeper focus on understanding the end markets and their competitors, what the competitors are doing, and making sure that we understand that and compete effectively. And this isn't -- this is an organizational focus. This is not just -- I’m not talking about our field, it's everybody. And understanding, each one of these competitive battles that we face, first recognizing those, understand what it's going to take to win and tracking them. And all these competitive battles add up, and there's no rounding error when it comes to one of these competitive battles. So it is an enhanced focus on market share. And we felt like now is the time to do this, given all the products that we have coming out. We want to make it -- like I said, we want to make the pipeline count not just for our patients, which is first and foremost, and our customers, but for our shareholders as well. So we felt that was the moment to do this. And we’re really excited about that. And yes, the expectation is overall in aggregate to grow at the market or higher. And we haven't done that in the recent past. And so in some cases, we need to exceed the market growth and make up for a couple areas where we're behind. But the expectation for every single one of our segments is to grow at least at the market share. And we've made that really clear, and as you talk to people in Medtronic, I think that message is out there. Your second question about the robot. Yes, I mean, the delays were driven by COVID. Yes, the software issues we've talked about in the past, we believe are resolved and we're in the final validation and verification. And the testing has gone really well. We've got surgeons working on these robots. And like I said, the feedback is great and we're excited. And we're going to hit our market release date here shortly. And what that means for us is that that triggers to file, the ability for us to file, which we talked about in the commentary, I mentioned in calendar Q1 for both CE Mark and U.S. IDE. So, yes, we feel like this has addressed. We've got a high level of confidence. And now, the excitement is building by the company, and with our surgeons that are working on this. So we're excited. And you asked about a market share forecast. I'm not prepared to give that right now. I mean, we're going up against a strong competitor. We're really excited about this. My time at Medtronic, I feel like we're in a position where you're defending high market shares from new competitors. It's going to be fun to be on the other end of that equation, and coming out a well-established 100% market share competitor, but coming out with some great technology, with the financial resources at Medtronic, a really energized field sales force. So, we're looking forward to this. I'm not going to give our market share forecast, but we're going to be a meaningful player in this market. Go big or go home, Vijay. We're going to be meaningful in this and we're excited. Vijay Kumar: I love that. Go big or go home. Congrats, guys. Operator: Your next question comes from the line of Bob Hopkins at Bank of America. Bob Hopkins: Hi, good morning, and thanks for taking the questions. Just one clarification and one question. On the clarification side, you mentioned talking about some disclosure you'll be making over the next couple of weeks about kind of changes at Medtronic. Is that all stuff that's going to come at the at the Analyst Day? Or are there disclosures coming before that? So that's just the clarification. And then the question is, Geoff I was really encouraged to hear your comments about improvements continuing into July and August. And obviously Karen made those as well. That's a huge issue for Medtronic and for all of medtech, because there is a lot of uncertainty out there. So, Geoff, I was wondering if you could just make some comments on just what you're seeing out there in July and August in terms of kind of the rescheduled procedures versus new demand. And what you're hearing from hospitals and patients, just any comments on that kind of the pace of the broader recovery would be much appreciated? Geoff Martha: All right. Thanks, Bob. One on the clarification, on the changes, these are changes we'll talk more about like you mentioned at our Investor Day. And I don't want to go too deep into them today. But the broad brush strokes are some structural changes that empower our businesses to make decisions and to be more -- and this is really getting at speed of decision making and being nimble and faster. And as you know, we're competing against a lot of focused, smaller focused companies, not just here, but in China and other places around the world. And then, but at the same time, allowing these businesses to benefit from very specific and meaningful areas where our scale makes a difference, like technology platforms. Anytime our businesses are pooling from broader technology platforms in Medtronic, they're able to iterate on a much more consistent, meaningful iteration on a much faster and consistent basis and also disrupt. Like we did with what we're doing with Micro right now, in the pacing space. Our manufacturing footprint to ensure a high-quality standard all the time, at the right price, at the right cost levels. So things, technology, manufacturing, our regional scale as we move into some of these regions, these are all areas that we want to make sure businesses can benefit from. But in terms of disclosures, I don't -- there's not going to be like disclosures before that. We'd be rolling this out to within the company over the next couple of weeks, a month of two. But I don't think there's going to be any more disclosures on that until we get to Investor Day to talk about it. And in terms of your question around the market improvement, it is encouraging. A couple comments there. First, there's a big difference depending on the therapy or product area and the business that we're in. We do have a wide range here things that are more urgent like neurovascular things that are more elective. Some of the areas like pelvic health or something like that. We're seeing by country it's different but we're seeing a much -- we've seen much of -- continued to see a much sharper recovery in the United States and Europe. China has been pretty steady. But the whole pile of geographies and all of the therapy areas, all of them are improving. And we're seeing sequential month over month improvement. I think the last time we had earnings call, we were talking about how things ended in April and we had some momentum into May. Well, that every week it's got -- every month it's gotten better into June, July and into the first couple weeks of August. We continue to see improvements here. And in terms of the patient fear, look the surveys that we've seen and conducted, that has been -- it's still out there, but it's been in my opinion mitigated quite a bit. And in the hospitals, and I just talked to another hospital's CEO on Friday. This is in the U.S. context. They seem very committed to staying, to keep open for business and serving patients. And, I think they also need it financially another shutdown, something they want to do. And then, the other thing that I think -- so these are all things that are going on out there. And we're participating in helping with patients fear and where we partnered with, The American Heart Association, American Stroke Association. And we're working with physicians, we're working with -- but the other area I want to highlight is the stuff that we're doing. Like I just mentioned, we're out there working with physicians, and their offices and hospitals. We're out there, staying focused on our customers. We're also helping them implement new technologies that really help in this COVID timeframe. Like our remote capabilities, especially in cardiac rhythm right now. That's making a big difference. We talked about the ventilator space. I mean, these were physician specific requests that came from individual hospitals around product features. And our response to this, and how fast we move, this makes a big difference. And the stories circulate within the hospital and the C-suites have been more engaged with us. And so, between the market coming back from a geography perspective, from a therapy perspective, and the actions that we've taken over the last couple of months, we're in a way better position than we thought we would be just three months ago. And we see the continued momentum. Now, everybody is a little nervous about the fall with the back-to-school. I just dropped off two college students in the last week. But like I said earlier, I do think hospitals are committed to staying open. And we're feeling better about like what maybe potential disruption. We don't feel -- we're not as worried about it as we were a couple months ago. Hope that helps. Bob Hopkins: Thank you. Ryan Weispfenning: Next question please, Regina? Operator: Next question comes from line of David Lewis with Morgan Stanley. David Lewis: Good morning. Just two for me. I'll ask them right up front for Geoff and Karen. So Geoff, I know it's early, but what's the profile Medtronic should aspire to relative to 4% and 8% top and bottom you gave back in 2018? And if we can't get specific numbers, I'm just sort of curious should investors expect that both of those numbers should move higher? Or is the focus more on revenue for the intermediate-term? And then Karen, just kind of related question. There's been a series of often on balance sheet transactions, most notably the recent M&A and Blackstone. So that clearly suggests the company's desire to accelerate growth. What does it tell us, if anything, Karen about sort of the flexibility of the P&L in terms of margin opportunities going forward? Thanks so much. Geoff Martha: I'll take a stab, David, first. Thanks for the question. Let me take a stab at it, and then I'll hand it off to Karen. But on the 8% EPS, and we're committed to that, right? So, we talk about market share and we talk about growth. Let me be clear, it's not at the expense of that 8% EPS growth, and our free cash flow conversion, which we've worked so hard to improve over the last couple years. So, we're not going to take a step back there, we're committed to that. And as we grow more, right, as we grow at the market more as an aggregate which would be a meaningful improvement over the last couple years, and take share, the growth will get higher, we'll have some optionality of what to do with that incremental earnings. But we're committed to that 8%. And we'll decide as that growth gets there, what we're going to do with the extra EPS, I'd like to invest some of it. And we'll see what we do with the rest here. But with that, maybe I'll turn it over to Karen to also comment. Karen Parkhill: Yes. Thanks, Geoff. And thanks, David, for the questions. Yes, we have a strong balance sheet. And we have been using that to help our growth. And we've supplemented that, as you mentioned with partners like Blackstone to help us accelerate that growth. In terms of the flexibility of the P&L for margin going forward, what I would say is that our bias is going to be on driving revenue acceleration higher and keeping it consistent. And so, given that bias, we will be focused on continuing to invest to ensure that our pipeline remains as full as it has been in the recent past. So, could margins improve? Yes, a little bit. But we're more committed to driving that revenue growth acceleration and maintaining a bottom line EPS of 8% plus, then we are on dropping significant amount to the bottom line. We'll be focused more on investing. Hope that helps. David Lewis: Super helpful. Thanks so much. Ryan Weispfenning: Thanks, David. Next question, please? Operator: Your next question comes from the line of Robbie Marcus with JP Morgan. Robbie Marcus: Thanks for taking the question. And I'll be the first to tell you I did kind of like the video format. It was good to see you after being virtual for so long. Maybe on the question, and I'll kind of loop two in here. The first is we're seeing you year-over-year increases in R&D, while we're seeing most of your peers down year-over-year. You're clearly leaning in on R&D. I was wondering where are these dollars going. What are the projects that you're seeing and you're investing in? And then maybe along those lines, you're also clearly investing heavily in diabetes. There was speculation a while ago, maybe you'd exit that business. It looks to me less likely given how much you're putting in into resources here. What's the latest thoughts? You have new management, lots of investment there. How should we be thinking about this business? And is this a three to five year turnaround story? Or is it something we could see in the shorter-term? Thanks. Geoff Martha: Okay. Thanks, Robbie, lot into those questions there. First, thanks for the compliment on the video. I'm glad it went well. My wife was skeptical, but I thought it was okay. We'll see how we go going forward here. In terms of the R&D increases, yes, we want to put more into R&D, both and be creative. And when I look at R&D, we're looking at traditional R&D offer income statement, these creative third party partnerships like Blackstone, which have a very good return on them, are also something we want to use, and are inorganic. I mean, because most of what we're buying is technology, technology oriented tuck-ins, which are all somewhere on our path to commercialization or just been commercialized. So, all of this gets back to investing in areas in our business. We just have a lot of great ideas. The old idea that our eyes are bigger than our stomach. We want to get more R&D capability here. We've got just to list some of the products, we are talking about our pipeline today that's coming out, right. But the R&D and there's some R&D that needs to go into sustaining that and iterating that things like, spinal robotics and things like that. I mean, we're not done. We're just getting started. So, there's a lot more to go into there, but some of the things that are on the pipeline like already in that's a multibillion dollar opportunity there. The EV ICD, I'll start with cardiac here, PulseSelect Pulsed Field Ablation, I mean, just those three are, I'd call more medium-term for us and are very exciting, and I think could use more investment to speed up and drive bigger impact. And in RTG, there's always more to invest in neurovascular. Brett Wall and Stacey Pugh to make sure of that, there's lots of products there. And that's a high growth area. Like I mentioned, DBS, we have the directional lead system coming out. We want to invest in closed-loop. I just think, look, neuromodulation is a big growth opportunity for the industry, for the company, and I think it's going to have a huge impact on patients. And then MITG, obviously, the soft tissue robot, we talked about the timeline there. But we still have to commercialize that, that's going to take some investment, may not show up in the R&D line, but we need to invest there. And we mentioned in the commentary, some of the products are starting to come out from our digital surgery acquisition this touch surgery enterprise, very excited about that as we move, we believe we're leading in robotic soft tissue robotics, the AI and side of it. And so there's a lot of opportunity there. And then of course, diabetes, we've got to catch up on the sensor side, and we're -- I don't know everybody picked up, but we're really excited about the sensor pipeline here. I wish it were happening even faster, but it is accelerated from what we -- we're well into the synergy trial enrollment rather and getting great feedback on that. So there's lots of opportunities for R&D investment, and that's probably, I don't know, 70%, 80% of what we're talking about internally, is this pipeline and how do we feed it, how do we speed it up. So, very excited about that. And then, speaking on diabetes, you said three to five years, I'm not even going to ask Sean this question, because I know the answer is not three to five years, it's going to be faster than that. And I think when we get 70%, 80% out there, it's going to be a big step forward or like I mentioned, our sensor pipeline, which is the weak spot here, that is, we feel good about that. And again, I wish it were faster, but it isn't three to five years. And the rumors about diabetes, that they didn't come from us. I mean, we're committed to this and we've never blinked and we're not going to. Robbie Marcus: Thanks a lot. Ryan Weispfenning: Thanks, Robbie. Next question, please, Regina? Operator: Your next question comes from the line of Joanne Wuensch with Citibank. Joanne Wuensch: Good morning, everybody. As has been communicated with investors this morning, one of the themes coming across is a sense of being reinvigorated or quote a different Medtronic. So what do you see just because you're relatively new in the CEO role and you get to do it in the midst of a pandemic? What do you see that is different that how you're going to make your mark on the company? And on the other side of this pandemic, how do you think Medtronic is going to look different? Because it seems to me that the way Medtronic approached managing its employees during the pandemic may be somewhat different than the way others have. Thank you. Geoff Martha: In terms of a reinvigorated, I think we do feel reinvigorated and it's in large part, because of where we sit right now as a company. I mean, this pipeline is exciting, and it's something that we've been investing in for a long time. And look, the COVID has extracted a huge human toll and an economic toll. So I'm looking for bright spots coming out of COVID. And one of them has been the ability for during this time our leadership team to sit down together. Like I said, a lot of Zoom calls and some face to face, but and really look at where we are as a company and take a step back. And what we're seeing is way more opportunities than challenges. But top of that, I mean, look, we've got our mission, especially during a pandemic like this really shows how valuable that mission is. And it helps us clarify our decisions, and really helps us in our opinion stand out relative to others, and how we react and how we show up. And so we've always had that and that has shown even just -- we're reminded how powerful that is during a crisis like we face now. We've got a very -- we've got great technology, great market positions. We've got a very experienced leadership team, and I come back to this pipeline. And so when we started to look at all this, we feel like there's just a huge opportunity. We want to make this pipeline count. And so, that's why we're excited. And if it feels like we're reinvigorated, that's good. I don't know, if I want to use that word, but I can tell you that we're excited, because of all this and the opportunity. And it's not just like, hey, here's the pipeline, and it's going to work its way through and then there's like peaks and troughs. That's not it. We're refilling this pipeline. I just mentioned all these, I just went through the last question all of these things about the R&D, where we're putting it. There's so much to do, so much opportunity. So, yes we are excited. And that's why we also are focusing on this market share opportunity. We want to make this pipeline count. And how we look different? One, in the near-term, we want to be growing at or above the market. So, whatever the recovery is, it's hard to forecast. We're trying our best as you guys are to forecast the recovery, but we want to be on the leading edge of that, and doing better relative to our competitors. And, and our pipeline is going to lead the way and we're going to have great commercial execution here. And so that should be a meaningful increase to our growth relative to our competition. So, that looks different. And look, our employees have always had a strong loyalty and allegiance to Medtronic. But I think that's increased over the last couple of months, as people realized what a -- how much the mission means, but we still have work to do. And working on things like what is our role here and some of these social justice issues that are out in the communities that spill into our offices. And so you're going to see us more aggressive on those taking stronger stance on some of those issues. But over time, longer-term, we want to put the tech in medtech. And we want to shift, we want to pool in some of these digital technologies to change our offerings. And overtime, we're very device centric. In addition to the devices, we want to pull in data and analytics, and you start to see that in pockets of Medtronic, like with the neutrino acquisition, diabetes, the digital surgery acquisition and MITG for the soft tissue robot. We're working with -- partnering with companies like Viz.ai for stroke detection. And so, having our offerings be smarter and self-learning, and our offerings providing a lot of data and insights in addition to therapy back to our customers, I think this is an area that that this is going to take some time. But this is something we're committed to. Joanne Wuensch: Thank you. Ryan Weispfenning: Thanks, Joanne. Next question, please, Regina? Operator: Your next question comes from the line of Larry Biegelsen with Wells Fargo. Larry Biegelsen: Good morning. Thanks for taking the question. And mine are for Karen. Just Karen, one clarification, how much of the extra week was offset by reduced bulk purchases in the quarter? And for my question, last quarter, you gave some helpful commentary on the exit rates in the last month. What did you see in July relative to what looks like about a negative 9% organic year-over-year growth rate you're guiding to in fiscal Q2? And can you get to flat or growth in fiscal Q3? Thanks for taking the questions. Karen Parkhill: Thank you. Thank you, Larry. So, in terms of the extra week, basically, all of it was offset by the reduction in customer bulk purchases. So, the net effect was essentially very minimal. In terms of the monthly trends that we're seeing, we're not going to give year-over-year monthly comparisons. And that's really because the reduction in bulk sales and the different number of selling days in the quarter can make that confusing. But I would want you to take away that our -- and Jeff talked about this, our average daily sales rate saw a significant step-up in May, and then again in June, and that continued into July and August. And we believe this trend will continue. We've signaled that we believe our second quarter should see improvement, roughly equal to the improvement that we saw between the fourth quarter and the first quarter. And just to remind you, the fourth quarter declined 25%, the first quarter 17%. That's a differential of about 8%. That's the kind of improvement that we would expect to see in the second quarter. And then we would expect to continue that improvement into the back-half. And by the time we reach our fourth quarter, we would expect to be back to more normal growth when you look at it on a two year stack basis. Larry Biegelsen: Thank you. Ryan Weispfenning: Thanks, Larry. I think we have time for maybe two more questions. We can take the next one, Regina. Operator: Our next question comes from the line of Danielle Antalffy with SVB Leerink. Danielle Antalffy: Hey, good morning, guys. Thanks so much for taking the question. And I second Robbie's comments on the visual, too, so thanks for that. If I could just ask a question, Geoff, on the commentary around market share gains. And I'm curious, just more specifically, tied to sort of what you're talking about with the new infrastructure investments and things like that that we'll hear more about on the Analyst Day, how much of this sort of reinvigorated effort around really gaining market share and being more aggressive is tied to things like that versus potentially having to build out further from a product perspective and innovate even more on the pipeline? And that's my only question. Thank you so much. Geoff Martha: Well, on the innovation side, I mean, like I said, we feel like we've got a great pipeline, the best we've had, and it's coming to fruition now and we've got more out there in the medium and long-term. But we're not ever going to be satisfied on our pipeline. I mean, innovation is the lifeblood of the company. So we're always going to want to invest more and really just not -- ultimately the ultimate judge here would be the level of innovation and the outcomes we can produce with these technologies, both for patients and economic outcomes for the health system. So that's the ultimate. But we don't want to be outspent either. So we are investing more, using these creative like the Blackstone partnership, using our balance sheet more, trying to get more efficient. We're always going to try to get more efficient in R&D. So we're never going to be satisfied with innovation. Omar used to talk about it. He talks about health care as being like a by definition, an unlimited demand. As soon as you solve one problem, people want another problem solved and they want to solve faster. So we're going to keep going on the innovation. And the market share, it's really two things that we're going to need to do. Well, three things, really. You need to have the products right? You have the pipeline, which we've talked about. The other two areas that we've talked about is structurally, allowing to help increase that innovation, allowing our business units to have more leverage, the pool to be more nimble and faster to compete with. The marketplace in medtech is pretty competitive. Like I said, we face a lot of smaller and maybe more focused competition. And I don't really like this idea. Well, they're smaller, so they should grow faster. I don't -- I'm not a believer in that. And so neither is our leadership team, for that matter. And we're not accepting that. So, we want to treat our businesses and give them the ability to compete against anybody, whether it's a big, well-funded or competitor with lots of technology or more established competitor or a smaller up and coming competitor, we want to be able to compete with all. So it's making some structural changes to better position them for that. And then the third is just the cultural piece, it's just setting that expectation that we're always going to be a mission driven company. We're always going to be an innovation driven company. We're always going to be that company that's pushing the envelope here and starting new therapy areas like an RDN. We're going to be that company. But we also want to be the company that is able to kind of hold the share in these markets that we established. And in some cases like soft tissue robotics, where we weren't the first to come in as a meaningful second. And I think there's room for improvement and in the mindset of the company on competing like that. So that's a culture. So pipeline, always first, some structural changes that we think we can work through without too much disruption here, and the cultural changes around expectations on competing. Danielle Antalffy: Thank you so much. Ryan Weispfenning: Thanks, Danielle. We'll take the last question, please, Regina. Operator: Our final question comes from the line of Raj Denhoy with Jefferies. Raj Denhoy: Good morning. Wondering if maybe I could ask you about Companion Medical. You talked about the potential for that product in the diabetes market, but maybe you could share a little bit about your internal projections for revenue growth for that? And when it can start to be a meaningful contributor to your growth? Geoff Martha: Well, first on Companion, we haven't finalized the acquisition, so we're limited in what we can say, but Sean is the real champion and architect behind on that deal. And so maybe Sean, Sean Salmon's on the phone here. I'll turn it over to Sean for some comments. Sean Salmon: Yes. Great, thanks. Thanks for the question Raj. Yes, as Geoff said, the deal is not yet finalized, but the opportunity is very attractive. You'd heard Geoff’s commentary, so there's about 12 times the number of patients. We think, by our modeling, it's about 13.5 million patients worldwide, who are using multiple daily injections to treat their diabetes. And it's a very, very underpenetrated opportunity. So for us to go into that market and add value to those who either choose to be there or have to be there, because of other considerations is where we want to meet those patients. And this really dovetails very nicely into our improving sensor pipeline, and adding the capabilities that we've added in the company over time. Those building blocks for the powerful AI and data science capabilities, which we think when deployed against knowing how much insulin you're getting, at what time, you can markedly improve the outcomes for patients who choose to use multiple daily injections. So, it does a few things right? We can capture more of the patients who are upstream and maybe patients who get comfortable with technology into some other solutions that we have in our automated insulin delivery systems. Raj Denhoy: Great. And maybe just Geoff one follow-up for you relative to acquisitions broadly right, so Companion and other kind of tuck-in deals you've talked about. Should one assume that you have no appetite for larger deals? Or we continue to focus really just on the tuck-in side of things, really just any broader thoughts here would be helpful? Geoff Martha: The focus is on the tuck-ins. And the tuck-ins can get up to billion dollars or low billions. But that's the focus. That's the focus. Like where we are right now, and the tuck-ins will help us. But we're not focused beyond that. Raj Denhoy: Great. Thank you. Ryan Weispfenning: Thanks, Raj. Geoff, would you like to conclude? Geoff Martha: Okay. Well, thanks for the questions. And look, I really appreciate, we all really appreciate your support and interest in Medtronic. And we're looking forward to presenting more details of our longer-term strategy at our October 14, Investor Day. And then updating you on our quarterly progress on our Q2 earnings call, which we anticipate holding on November 24. So thanks for joining us today. Stay healthy and safe, and have a great day. Operator: Ladies and gentlemen, that will conclude today's call. Thank you all for joining. And you may now disconnect.MDT Ratings Summary
MDT Quant Ranking
Related Analysis
Medtronic Exceeds Q1 Earnings Forecasts and Raises Full-Year Guidance for 2025
Medtronic (NYSE:MDT) reported first-quarter earnings on Tuesday that exceeded analyst expectations and boosted its guidance for fiscal 2025.
The medical device company posted earnings per share (EPS) of $1.23 for Q1, surpassing the consensus estimate of $1.20. Revenue for the quarter was in line with forecasts at $7.9 billion.
Medtronic's adjusted gross margin for the quarter stood at 65.9%, slightly lower than the 66.4% recorded in the same period last year but higher than the 65.5% analysts had predicted. The adjusted operating margin came in at 24.4%, matching expectations but marginally down from 24.8% in the previous year.
Looking forward, Medtronic raised its fiscal 2025 non-GAAP EPS guidance to a range of $5.42 to $5.50, slightly up from the previous projection of $5.40 to $5.50. This reflects an anticipated EPS growth of 4% to 6% for the year. Additionally, the company increased its forecast for organic revenue growth to a range of 4.5% to 5%, up from its earlier estimate of 4% to 5%.
Medtronic's Earnings Overview for Q4 Fiscal Year 2024
- Medtronic exceeded EPS estimates of $1.45, and reported revenue of $8.59 billion, surpassing expectations.
- The company demonstrated operational efficiency with a 4.5% increase in adjusted earnings per share for the full fiscal year, despite a decrease in adjusted EPS for the quarter.
- Revenue growth was driven by strong performance across multiple business segments, with significant regulatory approvals highlighting Medtronic's innovation and growth potential.
Medtronic (NYSE:MDT), a global leader in medical technology, services, and solutions, reported its earnings for the fourth quarter of fiscal year 2024 on Thursday, May 23, before the market opened. The company's earnings per share (EPS) of $1.46 slightly surpassed the estimated EPS of $1.45, showcasing Medtronic's ability to exceed analyst expectations. Additionally, Medtronic reported revenue of approximately $8.59 billion, exceeding the estimated revenue of about $8.45 billion. This performance indicates a positive outcome for Medtronic in the recent May earnings report, reflecting the company's resilience and strategic growth initiatives in the face of industry challenges.
Despite facing a decrease of 7.5% in adjusted EPS from the same quarter in the previous year, Medtronic's financial results highlight its operational efficiency and market adaptability. The company's GAAP EPS, which includes various one-time adjustments such as restructuring and associated costs, was significantly lower at 49 cents, down 44.3% from the year-ago quarter. However, for the full fiscal year, Medtronic reported adjusted earnings of $5.53 per share, an increase of 4.5% from the previous year, beating the Zacks Consensus Estimate by 6.3%. This demonstrates Medtronic's ability to navigate through fiscal challenges while still delivering growth.
Medtronic's revenue growth was attributed to strong performance across several of its businesses, including Cranial & Spinal Technologies, Diabetes, Cardiac Pacing, and Surgical. The company's worldwide revenues for the quarter were $8.59 billion, a slight increase of 0.5% on a reported basis and 5.4% on an organic basis from the year-ago period, exceeding the Zacks Consensus Estimate by 1.8%. The total revenues for fiscal 2024 reached $32.36 billion, up 3.6% from the previous year and slightly above the Zacks Consensus Estimate by 0.5%. This revenue growth, coupled with strategic regulatory achievements such as receiving U.S. FDA approval for its Evolut™ FX+ TAVR system and Inceptiv™ closed-loop spinal cord stimulator, underscores Medtronic's broad-based, durable growth across various segments.
Furthermore, Medtronic's financial health is evident in its cash flow from operations for FY24, which was $6.8 billion, a 12% increase from the previous year. The company's free cash flow rose by 14% to $5.2 billion, demonstrating its strong cash generation capabilities. Medtronic has been proactive in returning value to its shareholders, with $5.5 billion returned in FY24, including $1.6 billion through net share repurchases in Q4 alone. The increase in its quarterly dividend to $0.70 per share, marking the 47th consecutive year of dividend increases, reflects Medtronic's commitment to shareholder value and its confidence in the company's financial stability and growth prospects.
In summary, Medtronic's latest earnings report for the fourth quarter of fiscal year 2024 highlights the company's ability to exceed expectations, navigate challenges, and continue its growth trajectory. With strategic investments in innovation, a focus on operational efficiency, and a commitment to returning value to shareholders, Medtronic is well-positioned for sustained success in the healthcare sector.
Medtronic Shares Climb Following Q3 Beat
Shares of Medtronic (NYSE:MDT) climbed more than 3% pre-market today following the announcement of third-quarter results that exceeded analyst expectations, prompting the company to uplift its financial outlook for the 2024 fiscal year. Medtronic reported an adjusted earnings per share (EPS) of $1.30, which was $0.04 above the analyst consensus of $1.26. Moreover, the company's quarterly revenue reached $8.1 billion, outperforming the anticipated $7.95 billion by analysts.
Medtronic updated its forecast for organic revenue growth in fiscal 2024, increasing it from the initially projected 4.75% to a range of 4.75% to 5%. Furthermore, the adjusted EPS outlook for 2024 was adjusted upwards from the previous range of $5.13 to $5.19 to a new range of $5.19 to $5.21, attributed to the strong performance in the third quarter.
Medtronic Double Downgraded at UBS
Medtronic (NYSE:MDT) shares have been double-downgraded to Sell from Buy by UBS due to anticipated near-term sales and EPS downside risk. The new price target is $79 per share, a significant drop from the prior target of $127. The analysts believe that Medtronic's ongoing transformation will require more time, and lack confidence that the company can achieve sustainable mid-single-digit top-line growth and consistent operating margin improvement.
UBS predicts that Medtronic's sales will grow at a CAGR of 3.8%, which is lower than the consensus estimate of 4.8%. Additionally, UBS' survey shows minimal diabetes share gains. It expects that in 2024 and 2025, the company's EPS will be lower than consensus estimates by low-single-digits and high-single-digits, respectively, mainly due to lower sales. While Medtronic may gain marginal share in some businesses, such as Evolut FX in TAVR (Transcatheter Aortic Valve Replacement), the company is losing share in other areas such as cryo, peripheral, and diabetes.
Medtronic Reports Q3 Beat & Raises Guidance
Medtronic (NYSE:MDT) reported its Q3 results, with both EPS of $1.30 and revenue of $7.7 billion coming in better than the Street estimates of $1.27 and $7.54 billion, respectively.
Better-than-expected revenue was driven by beats across all of its business segments, with headwinds abating in ventilator sales and product availability.
The company raised its 2023 guidance, now expecting FX rates to negatively impact Q4 revenue by $165-215 million and guided to 2023 EPS of $5.28-$5.30 (prior guidance of $5.25-5.30), which includes an $0.21 FX headwind as of current rates.
The company continues to expect expense reductions to help offset headwinds e.g. inflation, interest, FX, and taxes. Additionally, the company noted it expects organic growth of 4.5-5.0% in Q4.
Medtronic Reports Q3 Beat & Raises Guidance
Medtronic (NYSE:MDT) reported its Q3 results, with both EPS of $1.30 and revenue of $7.7 billion coming in better than the Street estimates of $1.27 and $7.54 billion, respectively.
Better-than-expected revenue was driven by beats across all of its business segments, with headwinds abating in ventilator sales and product availability.
The company raised its 2023 guidance, now expecting FX rates to negatively impact Q4 revenue by $165-215 million and guided to 2023 EPS of $5.28-$5.30 (prior guidance of $5.25-5.30), which includes an $0.21 FX headwind as of current rates.
The company continues to expect expense reductions to help offset headwinds e.g. inflation, interest, FX, and taxes. Additionally, the company noted it expects organic growth of 4.5-5.0% in Q4.
Medtronic Downgraded at RBC Capital, Shares Down 4%
Medtronic plc (NYSE:MDT) shares closed more than 4% lower yesterday after RBC Capital downgraded the company to Sector Perform from Outperform and lowered its price target to $89 from $102.
According to analysts, there is significant dissatisfaction among investors regarding the way the company's management has handled several issues (e.g. warning letter, supply impact, RDN). Additionally, they believe that the company's recovery has been slower than expected and that it is facing ongoing challenges due to macroeconomic conditions. While the situation may improve in the future, it is unlikely that the company will perform significantly better than its competitors, due to the loss of credibility it has experienced.
The company cut its fiscal 2023 organic growth outlook from approximately 5% in Feb to 1.4-1.6% in Nov due to supply constraints as well as slower recovery in certain sub-segments such as neuromodulation, TAVR, basic coronary PCI, and other general surgery procedures. Full-year EPS outlook was lowered throughout the year as well due to lower organic sales growth, and pressures related to FX, inflation, and supply. The company now expects 2023 EPS to be in the range of $5.25-5.30 (down 5.7-6.6% year-over-year).
